Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
GERON Corporation has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned across 2 distinct examiners and 2 distinct art units, showing that the current prosecution activity is spread across separate examination channels.
QIAN, CELINE X is the busiest examiner, with 1 pending matter. The available data does not indicate concentration with one examiner, so docketing should focus on matter-specific deadlines and arguments. Consistent treatment of biotechnology terminology can help avoid unnecessary divergence between responses handled in different examination assignments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, CELINE X | 1 | 47.5% | +17.4% |
| COPPINS, JANET L | 1 | 72.5% | +26.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18394773 | METHODS OF TREATING MYELODYSPLASTIC SYNDROME AND MONITORING THE TREATMENT | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17670278 | Combination Treatment for Hematological Cancers | COPPINS, JANET L | 28d |
| 18394773 | METHODS OF TREATING MYELODYSPLASTIC SYNDROME AND MONITORING THE TREATMENT | QIAN, CELINE X | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18394773 | METHODS OF TREATING MYELODYSPLASTIC SYNDROME AND MONITORING THE TREATMENT | QIAN, CELINE X | 1637 | §102§103 | Final Rejection | — | Pending | Dec 22, 2023 |
| 17670278 | Combination Treatment for Hematological Cancers | COPPINS, JANET L | 1628 | §112 | Final Rejection | 28d | Pending | Feb 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGERON Corporation has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Celine X Qian has the most, with 1 of GERON Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.